The estimated Net Worth of Kurt Oreshack is at least $66.1 mil dollars as of 24 November 2020. Mr Oreshack owns over 7,500 units of Maravai Lifesciences stock worth over $66,075 and over the last 4 years he sold MRVI stock worth over $0.
Mr has made over 1 trades of the Maravai Lifesciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 7,500 units of MRVI stock worth $202,500 on 24 November 2020.
The largest trade he's ever made was buying 7,500 units of Maravai Lifesciences stock on 24 November 2020 worth over $202,500. On average, Mr trades about 625 units every 0 days since 2020. As of 24 November 2020 he still owns at least 7,500 units of Maravai Lifesciences stock.
You can see the complete history of Mr Oreshack stock trades at the bottom of the page.
Kurt Oreshack is the VP, Gen. Counsel & Sec. at Maravai Lifesciences.
Mr Oreshack is 40, he's been the VP y Gen. Counsel & Sec. of Maravai Lifesciences since . There are 4 older and no younger executives at Maravai Lifesciences. The oldest executive at Maravai Lifesciences Holdings, Inc. is Carl W. Hull, 62, who is the Co-Founder, Chairman & CEO.
Kurt's mailing address filed with the SEC is C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO, CA, 92121.
Over the last 4 years, insiders at Maravai Lifesciences have traded over $97,620,365 worth of Maravai Lifesciences stock and bought 174,388 units worth $4,706,376 . The most active insiders traders include Investment Xi Llcmaravai Li..., Gregory T Lucier y Robert B Hance. On average, Maravai Lifesciences executives and independent directors trade stock every 142 days with the average trade being worth of $9,901,814. The most recent stock trade was executed by Investment Xi Llcmaravai Li... on 28 May 2024, trading 9,940,974 units of MRVI stock currently worth $97,620,365.
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in three segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The Protein Detection segment sells labeling and detection reagents for researchers in immunohistochemistry, immunofluorescence, and glycobiology. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
Maravai Lifesciences executives and other stock owners filed with the SEC include: